Interações de Divalproato de sódio (valproato)

Divalproato de sódio (valproato) (Depakote), anticonvulsivante, tem 311 interações documentadas nas bulas da FDA e nas fichas informativas que indexamos (graves: 103; moderadas: 163; leves: 44; casos em que uma bula relata não haver interação significativa: 1). Cada item abaixo cita a frase em que se baseia. Esta página de medicamento é um ponto de partida, não um veredito para a sua situação.

Interações segundo a bula

Interações graves (103)

  • Ácido valproicoanticonvulsivanteGrave

    • with known hypersensitivity to divalproex sodium, sodium valproate, or valproic acid. (bula de Divalproato de sódio (valproato), Contraindicações)

  • ÁlcoolÁlcoolGrave

    Combinar álcool com medicamentos sedativos (opioides, benzodiazepínicos, medicamentos para dormir, relaxantes musculares) pode causar sonolência perigosa, respiração lenta e superdose. (NIAAA, Harmful Interactions: Mixing Alcohol with Medicines)

  • AlprazolambenzodiazepínicoGrave

    • Effects on Driving and Operating Machinery: Patients receiving • alprazolam XR should be cautioned against operating machinery or driving a motor vehicle, as well as avoiding concomitant use of alcohol and other central nervous system (CNS) depressant drugs. (bula de Alprazolam, Advertências e precauções)

  • AtazanavirantirretroviralGrave

    Drug Class Drugs within class that are contraindicated with REYATAZ Alpha 1-adrenoreceptor antagonist Alfuzosin Anticonvulsants Carbamazepine, phenobarbital, phenytoin Antiarrhythmics Amiodarone (with ritonavir), quinidine (with ritonavir) Antimycobacterials Rifampin Antineoplastics Apalutamide, encorafenib, irinotecan, ivosidenib Antipsychotics Lurasidone (with… (bula de Atazanavir, Contraindicações)

  • Azelastina + fluticasonaanti-histamínicoGrave

    • Avoid concurrent use of alcohol or other central nervous system (CNS) depressants with azelastine hydrochloride and fluticasone propionate nasal spray because further decreased alertness and impairment of CNS performance may occur. (bula de Azelastina + fluticasona, Advertências e precauções)

  • Beladona + ópioopioideGrave

    …AND MISUSE; LIFE-THREATENING RESPIRATORY DEPRESSION; ACCIDENTAL EXPOSURE; NEONATAL OPIOD WITHDRAWAL SYNDROME; and RISKS FROM CONCOMITANT USE WITH ALCOHOL, BENZODIAZEPINES OR OTHER CNS DEPRESSANTS Addiction, Abuse, and Misuse Belladonna and opium suppositories expose patients and other users to the risks of opioid addiction, abuse, and misuse, which can lead to… (bula de Beladona + ópio, Advertência em caixa preta)

  • BrivaracetamanticonvulsivanteGrave

    Children under the age of two years are at a considerably increased risk of developing fatal hepatotoxicity, especially those on multiple anticonvulsants, those with congenital metabolic disorders, those with severe seizure disorders accompanied by mental retardation, and those with organic brain disease. (bula de Divalproato de sódio (valproato), Advertência em caixa preta)

  • BuprenorfinaopioideGrave

    Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (bula de Buprenorfina, Advertência em caixa preta)

  • BupropionaantidepressivoGrave

    Bupropion hydrochloride extended-release tablets (XL) are contraindicated in patients undergoing abrupt discontinuation of alcohol, benzodiazepines, barbiturates, and antiepileptic drugs [see Warnings and Precautions (5.3) and Drug Interactions (7.3)] . (bula de Bupropiona, Contraindicações)

  • Concomitant use of opioids or a barbiturate with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (bula de Butalbital + ácido acetilsalicílico + cafeína + codeína, Advertência em caixa preta)

  • Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (bula de Butalbital + paracetamol + cafeína + codeína, Advertência em caixa preta)

  • ButorfanolopioideGrave

    Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (bula de Butorfanol, Advertência em caixa preta)

  • CabotegravirantirretroviralGrave

    …diphosphate glucuronosyltransferase (UGT)1A1 enzyme induction, which may result in loss of virologic response [see Drug Interactions ( 7.2 , 7.3 ), Clinical Pharmacology ( 12.3 )] : o Anticonvulsants: Carbamazepine, oxcarbazepine, phenobarbital, phenytoin o Antimycobacterials: Rifampin, rifapentine Prior to initiation of VOCABRIA, note that use of CABENUVA (cabotegravir… (bula de Cabotegravir, Contraindicações)

  • Children under the age of two years are at a considerably increased risk of developing fatal hepatotoxicity, especially those on multiple anticonvulsants, those with congenital metabolic disorders, those with severe seizure disorders accompanied by mental retardation, and those with organic brain disease. (bula de Divalproato de sódio (valproato), Advertência em caixa preta)

  • CarbamazepinaanticonvulsivanteGrave

    Children under the age of two years are at a considerably increased risk of developing fatal hepatotoxicity, especially those on multiple anticonvulsants, those with congenital metabolic disorders, those with severe seizure disorders accompanied by mental retardation, and those with organic brain disease. (bula de Divalproato de sódio (valproato), Advertência em caixa preta)

  • Carbinoxaminaanti-histamínicoGrave

    Avoid concurrent use of Carbinoxamine Maleate Extended-Release Oral Suspension with alcohol or other central nervous system depressants because additional impairment of central nervous system performance may occur. (bula de Carbinoxamina, Advertências e precauções)

  • CenobamatoanticonvulsivanteGrave

    Children under the age of two years are at a considerably increased risk of developing fatal hepatotoxicity, especially those on multiple anticonvulsants, those with congenital metabolic disorders, those with severe seizure disorders accompanied by mental retardation, and those with organic brain disease. (bula de Divalproato de sódio (valproato), Advertência em caixa preta)

  • Cetaminadepressor do SNCGrave

    Benzodiazepines, Opioid Analgesics, or other CNS Depressants : Concomitant use may result in profound sedation, respiratory depression, coma, or death. (bula de Cetamina, Interações medicamentosas)

  • Cetirizinaanti-histamínicoGrave

    Avoid concurrent use of QUZYTTIR with alcohol or other CNS depressants because additional reduction in alertness and additional impairment of CNS performance may occur. (bula de Cetirizina, Advertências e precauções)

  • Cetoconazolantifúngico azólicoGrave

    This may potentiate and prolong hypnotic and sedative effects, especially with repeated dosing or chronic administration of these agents. (bula de Cetoconazol, Contraindicações)

  • Ciclobenzaprinarelaxante muscularGrave

    Based on its structural similarity to TCAs, concomitant use of TONMYA with: MAO inhibitors may be life-threatening [see Contraindications (4) ] , Alcohol, barbiturates, and other CNS depressants may increase the risk of adverse reactions associated with these drugs, Tramadol may increase the seizure risk, Guanethidine or other similar acting drugs may block the… (bula de Ciclobenzaprina, Interações medicamentosas)

  • CiprofloxacinofluoroquinolonaGrave

    Table 8: Drugs That are Affected by and Affecting Ciprofloxacin Drugs That are Affected by Ciprofloxacin Drug(s) Recommendation Comments Tizanidine Contraindicated Concomitant administration of tizanidine and ciprofloxacin is contraindicated due to the potentiation of hypotensive and sedative effects of tizanidine [see Contraindications ( 4.2 )]. (bula de Ciprofloxacino, Interações medicamentosas)

  • ClobazambenzodiazepínicoGrave

    Children under the age of two years are at a considerably increased risk of developing fatal hepatotoxicity, especially those on multiple anticonvulsants, those with congenital metabolic disorders, those with severe seizure disorders accompanied by mental retardation, and those with organic brain disease. (bula de Divalproato de sódio (valproato), Advertência em caixa preta)

  • ClonazepambenzodiazepínicoGrave

    Children under the age of two years are at a considerably increased risk of developing fatal hepatotoxicity, especially those on multiple anticonvulsants, those with congenital metabolic disorders, those with severe seizure disorders accompanied by mental retardation, and those with organic brain disease. (bula de Divalproato de sódio (valproato), Advertência em caixa preta)

  • Clonidinaagonista alfa-adrenérgicoGrave

    Avoid use with other central nervous system (CNS) depressants ( 5.3 ) (bula de Clonidina, Advertências e precauções)

  • CodeínaopioideGrave

    Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (bula de Codeína, Advertência em caixa preta)

  • DarunavirantirretroviralGrave

    …elbasvir/grazoprevir Lipid modifying agents: lomitapide, lovastatin, simvastatin Opioid Antagonist: naloxegol PDE-5 inhibitor: sildenafil when used for treatment of pulmonary arterial hypertension Sedatives/hypnotics: orally administered midazolam, triazolam Co-administration of PREZISTA/ritonavir is contraindicated with drugs that are highly dependent on CYP3A for clearance… (bula de Darunavir, Contraindicações)

  • Darunavir + cobicistateantirretroviralGrave

    Alpha 1-adrenoreceptor antagonist: alfuzosin Anticonvulsants: carbamazepine, phenobarbital, phenytoin Anti-gout: colchicine, in patients with renal and/or hepatic impairment Antimycobacterial: rifampin Antipsychotics: lurasidone, pimozide Cardiac Disorders: dronedarone, ivabradine, ranolazine Ergot derivatives, e.g. dihydroergotamine, ergotamine, methylergonovine… (bula de Darunavir + cobicistate, Contraindicações)

  • CONTRAINDICATIONS Diphenoxylate hydrochloride and atropine sulfate is contraindicated in: • Pediatric patients less than 6 years of age due to the risks of respiratory and central nervous system (CNS) depression (see WARNINGS ). (bula de Difenoxilato + atropina, Contraindicações)

  • DoravirinaantirretroviralGrave

    These drugs include, but are not limited to, the following: the anticonvulsants carbamazepine, oxcarbazepine, phenobarbital, phenytoin the androgen receptor inhibitor enzalutamide the antimycobacterials rifampin, rifapentine the cytotoxic agent mitotane St. (bula de Doravirina, Contraindicações)

  • Alpha 1-adrenoreceptor antagonist: alfuzosin Anticonvulsants: carbamazepine, phenobarbital, phenytoin Antimycobacterial: rifampin Antipsychotics: lurasidone, pimozide Ergot Derivatives: dihydroergotamine, ergotamine, methylergonovine Herbal Products: St. (bula de Elvitegravir + cobicistate + entricitabina + tenofovir, Contraindicações)

  • …virologic response and possible resistance to COMPLERA or to the class of NNRTIs [see Warnings and Precautions (5.7) , Drug Interactions (7) , and Clinical Pharmacology (12.3) ]: Anticonvulsants: carbamazepine, oxcarbazepine, phenobarbital, phenytoin Antimycobacterials: rifampin, rifapentine Glucocorticoid (systemic): dexamethasone (more than a single-dose)… (bula de Entricitabina + rilpivirina + tenofovir, Contraindicações)

  • ErtapenémantibióticoGrave

    The concomitant use of ertapenem and valproic acid/divalproex sodium is generally not recommended. (bula de Ertapeném, Advertências e precauções)

  • EslicarbazepinaanticonvulsivanteGrave

    Children under the age of two years are at a considerably increased risk of developing fatal hepatotoxicity, especially those on multiple anticonvulsants, those with congenital metabolic disorders, those with severe seizure disorders accompanied by mental retardation, and those with organic brain disease. (bula de Divalproato de sódio (valproato), Advertência em caixa preta)

  • Eszopiclonasedativo-hipnóticoGrave

    The use of LUNESTA with other sedative-hypnotics at bedtime or the middle of the night is not recommended. (bula de Eszopiclona, Advertências e precauções)

  • EtossuximidaanticonvulsivanteGrave

    Children under the age of two years are at a considerably increased risk of developing fatal hepatotoxicity, especially those on multiple anticonvulsants, those with congenital metabolic disorders, those with severe seizure disorders accompanied by mental retardation, and those with organic brain disease. (bula de Divalproato de sódio (valproato), Advertência em caixa preta)

  • FelbamatoanticonvulsivanteGrave

    Children under the age of two years are at a considerably increased risk of developing fatal hepatotoxicity, especially those on multiple anticonvulsants, those with congenital metabolic disorders, those with severe seizure disorders accompanied by mental retardation, and those with organic brain disease. (bula de Divalproato de sódio (valproato), Advertência em caixa preta)

  • Fenelzinainibidor da MAOGrave

    Phenelzine sulfate should not be used in combination with dextromethorphan or with CNS depressants such as alcohol and certain narcotics. (bula de Fenelzina, Contraindicações)

  • FenitoínaanticonvulsivanteGrave

    Children under the age of two years are at a considerably increased risk of developing fatal hepatotoxicity, especially those on multiple anticonvulsants, those with congenital metabolic disorders, those with severe seizure disorders accompanied by mental retardation, and those with organic brain disease. (bula de Divalproato de sódio (valproato), Advertência em caixa preta)

  • FenobarbitalbarbitúricoGrave

    Children under the age of two years are at a considerably increased risk of developing fatal hepatotoxicity, especially those on multiple anticonvulsants, those with congenital metabolic disorders, those with severe seizure disorders accompanied by mental retardation, and those with organic brain disease. (bula de Divalproato de sódio (valproato), Advertência em caixa preta)

  • FentanilaopioideGrave

    • Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (bula de Fentanila, Advertência em caixa preta)

  • Fentermina + topiramatoestimulante do SNCGrave

    Children under the age of two years are at a considerably increased risk of developing fatal hepatotoxicity, especially those on multiple anticonvulsants, those with congenital metabolic disorders, those with severe seizure disorders accompanied by mental retardation, and those with organic brain disease. (bula de Divalproato de sódio (valproato), Advertência em caixa preta)

  • FosamprenavirantirretroviralGrave

    …Hypericum perforatum ) Lipid modifying agents: Lomitapide, lovastatin, simvastatin Non-nucleoside reverse transcriptase inhibitor: Delavirdine PDE5 inhibitor: Sildenafil (Revatio) (for treatment of pulmonary arterial hypertension) Sedative/hypnotics: Midazolam, triazolam Hypersensitivity to fosamprenavir calcium or amprenavir (e.g., Stevens-Johnson syndrome). (bula de Fosamprenavir, Contraindicações)

  • FosfenitoínaanticonvulsivanteGrave

    Children under the age of two years are at a considerably increased risk of developing fatal hepatotoxicity, especially those on multiple anticonvulsants, those with congenital metabolic disorders, those with severe seizure disorders accompanied by mental retardation, and those with organic brain disease. (bula de Divalproato de sódio (valproato), Advertência em caixa preta)

  • GabapentinaanticonvulsivanteGrave

    Children under the age of two years are at a considerably increased risk of developing fatal hepatotoxicity, especially those on multiple anticonvulsants, those with congenital metabolic disorders, those with severe seizure disorders accompanied by mental retardation, and those with organic brain disease. (bula de Divalproato de sódio (valproato), Advertência em caixa preta)

  • HidrocodonaopioideGrave

    Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (bula de Hidrocodona, Advertência em caixa preta)

  • …ABUSE, AND MISUSE; LIFE-THREATENING RESPIRATORY DEPRESSION; ACCIDENTAL INGESTION; MEDICATION ERRORS; CYTOCHROME P450 3A4 INTERACTION; CONCOMITANT USE WITH BENZODIAZEPINES OR OTHER CNS DEPRESSANTS; INTERACTION WITH ALCOHOL; NEONATAL OPIOID WITHDRAWAL SYNDROME WARNING: ADDICTION, ABUSE, AND MISUSE; LIFE-THREATENING RESPIRATORY DEPRESSION; ACCIDENTAL INGESTION;… (bula de Hidrocodona + clorfeniramina, Advertência em caixa preta)

  • …ABUSE, AND MISUSE; LIFE-THREATENING RESPIRATORY DEPRESSION; ACCIDENTAL INGESTION; MEDICATION ERRORS; CYTOCHROME P450 3A4 INTERACTION; CONCOMITANT USE WITH BENZODIAZEPINES OR OTHER CNS DEPRESSANTS; INTERACTION WITH ALCOHOL; NEONATAL OPIOID WITHDRAWAL SYNDROME Addiction, Abuse, and Misuse Hydrocodone bitartrate and homatropine methylbromide exposes patients and… (bula de Hidrocodona + homatropina, Advertência em caixa preta)

  • …LIFE-THREATENING RESPIRATORY DEPRESSION; ACCIDENTAL INGESTION; NEONATAL OPIOID WITHDRAWAL SYNDROME; CYTOCHROME P4503A4 INTERACTION; RISKS FROM CONCOMITANT USE WITH BENZODIAZEPINES OR OTHER CNS DEPRESSANTS; and SERIOUS CARDIOVASCULAR AND GASTROINTESTINAL EVENTS WARNING: SERIOUS AND LIFE-THREATENING RISKS FROM USE OF HYDROCODONE BITARTRATE AND IBUPROFEN TABLETS Addiction,… (bula de Hidrocodona + ibuprofeno, Advertência em caixa preta)

  • Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (bula de Hidrocodona + paracetamol, Advertência em caixa preta)

  • HidromorfonaopioideGrave

    Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death . (bula de Hidromorfona, Advertência em caixa preta)

  • Hidroxizinaanti-histamínicoGrave

    Rarely, cardiac arrests and death have been reported in association with the combined use of hydroxyzine hydrochloride intramuscularly and other CNS depressants. (bula de Hidroxizina, Precauções)

  • Imipeném + cilastatinaantibióticoGrave

    The concomitant use of PRIMAXIN and valproic acid/divalproex sodium is generally not recommended ( 5.3 , 7.3 ). (bula de Imipeném + cilastatina, Advertências e precauções)

  • IsoniazidaantibióticoGrave

    To avoid phenytoin intoxication, appropriate adjustment of the anticonvulsant should be made 5,6 . (bula de Isoniazida, Interações medicamentosas)

  • Itraconazolantifúngico azólicoGrave

    Anticonvulsants Carbamazepine Not recommended 2 weeks before, during, and 2 weeks after TOLSURA treatment. (bula de Itraconazol, Interações medicamentosas)

  • LacosamidaanticonvulsivanteGrave

    Children under the age of two years are at a considerably increased risk of developing fatal hepatotoxicity, especially those on multiple anticonvulsants, those with congenital metabolic disorders, those with severe seizure disorders accompanied by mental retardation, and those with organic brain disease. (bula de Divalproato de sódio (valproato), Advertência em caixa preta)

  • LamotriginaanticonvulsivanteGrave

    Children under the age of two years are at a considerably increased risk of developing fatal hepatotoxicity, especially those on multiple anticonvulsants, those with congenital metabolic disorders, those with severe seizure disorders accompanied by mental retardation, and those with organic brain disease. (bula de Divalproato de sódio (valproato), Advertência em caixa preta)

  • LevetiracetamanticonvulsivanteGrave

    Children under the age of two years are at a considerably increased risk of developing fatal hepatotoxicity, especially those on multiple anticonvulsants, those with congenital metabolic disorders, those with severe seizure disorders accompanied by mental retardation, and those with organic brain disease. (bula de Divalproato de sódio (valproato), Advertência em caixa preta)

  • Levocetirizinaanti-histamínicoGrave

    Avoid concurrent use of alcohol or other central nervous system depressants with XYZAL. (bula de Levocetirizina, Advertências e precauções)

  • LevorfanolopioideGrave

    Risks from Concomitant Use with Benzodiazepines or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (bula de Levorfanol, Advertência em caixa preta)

  • Lopinavir + ritonavirantirretroviralGrave

    …Non-opioid Analgesic (selective blocker of Nav1.8 sodium channels): suzetrigine PDE5 Inhibitor: sildenafil (Revatio ® ) when used for the treatment of pulmonary arterial hypertension Sedative/Hypnotics: triazolam, orally administered midazolam KALETRA is contraindicated with drugs that are potent CYP3A inducers where significantly reduced lopinavir plasma concentrations… (bula de Lopinavir + ritonavir, Contraindicações)

  • LorazepambenzodiazepínicoGrave

    Caution patients receiving LOREEV XR against operating machinery or driving a motor vehicle as well to avoid the concomitant use of alcohol and other CNS depressant drugs during treatment ( 5.4 , 7 ) (bula de Lorazepam, Advertências e precauções)

  • MeropenémantibióticoGrave

    Risk of Breakthrough Seizures Due to Drug Interaction with Valproic Acid The concomitant use of meropenem and valproic acid or divalproex sodium is generally not recommended. (bula de Meropeném, Advertências e precauções)

  • Mesuximida (metossuximida)anticonvulsivanteGrave

    Children under the age of two years are at a considerably increased risk of developing fatal hepatotoxicity, especially those on multiple anticonvulsants, those with congenital metabolic disorders, those with severe seizure disorders accompanied by mental retardation, and those with organic brain disease. (bula de Divalproato de sódio (valproato), Advertência em caixa preta)

  • MetadonaopioideGrave

    Managing Risks from Concomitant Use with Benzodiazepines or Other CNS Depressants Concomitant use with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, is a risk factor for respiratory depression and death [see Warnings and Precautions ( 5.2 )]. (bula de Metadona, Advertência em caixa preta)

  • Metaxalonarelaxante muscularGrave

    If concomitant use with another CNS depressant is warranted, closely monitor for signs of respiratory depression and sedation, particularly during treatment initiation and dosage increases. (bula de Metaxalona, Advertências e precauções)

  • MidazolambenzodiazepínicoGrave

    WARNING: PERSONNEL AND EQUIPMENT FOR MONITORING AND RESUSCITATION AND RISKS FROM CONCOMITANT USE WITH OPIOID ANALGESICS AND OTHER SEDATIVE-HYPNOTICS Personnel and Equipment for Monitoring and Resuscitation Only personnel trained in the administration of procedural sedation, and not involved in the conduct of the diagnostic or therapeutic procedure, should administer… (bula de Midazolam, Advertência em caixa preta)

  • MorfinaopioideGrave

    Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (bula de Morfina, Advertência em caixa preta)

  • NalbufinaopioideGrave

    Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (bula de Nalbufina, Advertência em caixa preta)

  • Nalmefenoantagonista opioideGrave

    Risk of Recurrent Respiratory and CNS Depression : A recurrence of respiratory depression is possible, therefore, keep the patient under continued surveillance and administer repeat doses of ZURNAI using a new auto-injector with each dose while awaiting emergency medical assistance. (bula de Nalmefeno, Advertências e precauções)

  • Naltrexona + bupropionaantagonista opioideGrave

    …(e.g., buprenorphine) use, or acute opiate withdrawal [see Warnings and Precautions (5.4) and Drug Interactions (7.2) ] Patients undergoing an abrupt discontinuation of alcohol, benzodiazepines, barbiturates, and antiepileptic drugs [see Warnings and Precautions (5.3) and Drug Interactions (7.7) ] Concomitant administration of monoamine oxidase inhibitors (MAOI). (bula de Naltrexona + bupropiona, Contraindicações)

  • …(selective blocker of Na v 1.8 sodium channels): suzetrigine • Opioid antagonists: naloxegol • PDE5 inhibitor: sildenafil (Revatio ® ) when used for pulmonary arterial hypertension (PAH) • Sedative/hypnotics: triazolam, oral midazolam • Serotonin receptor 1A agonist/serotonin receptor 2A antagonist: flibanserin • Vasopressin receptor antagonists: tolvaptan ➢ Drugs that… (bula de Nirmatrelvir + ritonavir, Contraindicações)

  • OliceridinaopioideGrave

    Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (bula de Oliceridina, Advertência em caixa preta)

  • Olopatadinaanti-histamínicoGrave

    • Avoid concurrent use of alcohol or other central nervous system depressants with olopatadine hydrochloride nasal solution (nasal spray) ( 5.2 ). (bula de Olopatadina, Advertências e precauções)

  • Olopatadina + mometasonaanti-histamínicoGrave

    • Avoid concurrent use of alcohol or other central nervous system (CNS) depressants with RYALTRIS because additional reductions in alertness and additional impairment of CNS performance may occur. (bula de Olopatadina + mometasona, Advertências e precauções)

  • OxcarbazepinaanticonvulsivanteGrave

    Children under the age of two years are at a considerably increased risk of developing fatal hepatotoxicity, especially those on multiple anticonvulsants, those with congenital metabolic disorders, those with severe seizure disorders accompanied by mental retardation, and those with organic brain disease. (bula de Divalproato de sódio (valproato), Advertência em caixa preta)

  • Oxibato de sódiodepressor do SNCGrave

    Abuse or misuse of illicit GHB, either alone or in combination with other CNS depressants, is associated with CNS adverse reactions, including seizure, respiratory depression, decreases in the level of consciousness, coma, and death [see Warnings and Precautions ( 5.2 )]. (bula de Oxibato de sódio, Advertência em caixa preta)

  • OxicodonaopioideGrave

    Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (bula de Oxicodona, Advertência em caixa preta)

  • …LIFE-THREATENING RESPIRATORY DEPRESSION; ACCIDENTAL INGESTION; NEONATAL OPIOID WITHDRAWAL SYNDROME; CYTOCHROME P450 3A4 INTERACTION; and RISKS FROM CONCOMITANT USE WITH BENZODIAZEPINES OR OTHER CNS DEPRESSANTS Addiction, Abuse, and Misuse Oxycodone hydrochloride tablets exposes patients and other users to the risks of opioid addiction, abuse, and misuse, which can lead to… (bula de Oxicodona + paracetamol, Advertência em caixa preta)

  • OximorfonaopioideGrave

    Risks From Concomitant Use with Benzodiazepines or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (bula de Oximorfona, Advertência em caixa preta)

  • Risks from Concomitant Use with Benzodiazepines or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (bula de Paracetamol + codeína, Advertência em caixa preta)

  • …MITIGATION STRATEGY (REMS); LIFE-THREATENING RESPIRATORY DEPRESSION; ACCIDENTAL INGESTION; NEONATAL OPIOID WITHDRAWAL SYNDROME; and RISKS FROM CONCOMITANT USE WITH BENZODIAZEPINES OR OTHER CNS DEPRESSANTS Addiction, Abuse, and Misuse Pentazocine and Naloxone Tablets exposes patients and other users to the risks of opioid addiction, abuse, and misuse, which can lead to… (bula de Pentazocina + naloxona, Advertência em caixa preta)

  • PerampanelanticonvulsivanteGrave

    Children under the age of two years are at a considerably increased risk of developing fatal hepatotoxicity, especially those on multiple anticonvulsants, those with congenital metabolic disorders, those with severe seizure disorders accompanied by mental retardation, and those with organic brain disease. (bula de Divalproato de sódio (valproato), Advertência em caixa preta)

  • Risks from Concomitant Use with Benzodiazepines or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (bula de Petidina (meperidina), Advertência em caixa preta)

  • PregabalinaanticonvulsivanteGrave

    Children under the age of two years are at a considerably increased risk of developing fatal hepatotoxicity, especially those on multiple anticonvulsants, those with congenital metabolic disorders, those with severe seizure disorders accompanied by mental retardation, and those with organic brain disease. (bula de Divalproato de sódio (valproato), Advertência em caixa preta)

  • PrimidonaanticonvulsivanteGrave

    Children under the age of two years are at a considerably increased risk of developing fatal hepatotoxicity, especially those on multiple anticonvulsants, those with congenital metabolic disorders, those with severe seizure disorders accompanied by mental retardation, and those with organic brain disease. (bula de Divalproato de sódio (valproato), Advertência em caixa preta)

  • …PROMETHAZINE AND RESPIRATORY DEPRESSION IN CHILDREN; MEDICATION ERRORS; INTERACTIONS WITH DRUGS AFFECTING CYTOCHROME P450 ISOENZYMES; CONCOMITANT USE WITH BENZODIAZEPINES OR OTHER CNS DEPRESSANTS; NEONATAL OPIOID WITHDRAWAL SYNDROME Addiction, Abuse, and Misuse Promethazine HCl and Codeine Phosphate Oral Solution exposes patients and other users to the risks… (bula de Prometazina + codeína, Advertência em caixa preta)

  • QuininaantimaláricoGrave

    If concomitant administration with carbamazepine or phenobarbital cannot be avoided, frequent monitoring of anticonvulsant drug concentrations is recommended. (bula de Quinina, Interações medicamentosas)

  • RemifentanilaopioideGrave

    Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (bula de Remifentanila, Advertência em caixa preta)

  • RilpivirinaantirretroviralGrave

    Table 2: Drugs That are Contraindicated with EDURANT and EDURANT PED Drug Class Contraindicated Drugs in Class Clinical Comment Anticonvulsants Carbamazepine Oxcarbazepine Phenobarbital Phenytoin Potential for significant decreases in rilpivirine plasma concentrations due to CYP3A enzyme induction, which may result in loss of virologic response. (bula de Rilpivirina, Contraindicações)

  • RitonavirantirretroviralGrave

    WARNING: DRUG-DRUG INTERACTIONS LEADING TO POTENTIALLY SERIOUS AND/OR LIFE THREATENING REACTIONS Co-administration of NORVIR with several classes of drugs including sedative hypnotics, antiarrhythmics, or ergot alkaloid preparations may result in potentially serious and/or life-threatening adverse events due to possible effects of NORVIR on the hepatic metabolism… (bula de Ritonavir, Advertência em caixa preta)

  • RufinamidaanticonvulsivanteGrave

    Children under the age of two years are at a considerably increased risk of developing fatal hepatotoxicity, especially those on multiple anticonvulsants, those with congenital metabolic disorders, those with severe seizure disorders accompanied by mental retardation, and those with organic brain disease. (bula de Divalproato de sódio (valproato), Advertência em caixa preta)

  • Anticonvulsants: carbamazepine phenytoin phenobarbital ↓ sofosbuvir ↓ velpatasvir ↓ voxilaprevir Coadministration is not recommended. (bula de Sofosbuvir + velpatasvir, Interações medicamentosas)

  • TapentadolopioideGrave

    Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (bula de Tapentadol, Advertência em caixa preta)

  • TiagabinaanticonvulsivanteGrave

    Children under the age of two years are at a considerably increased risk of developing fatal hepatotoxicity, especially those on multiple anticonvulsants, those with congenital metabolic disorders, those with severe seizure disorders accompanied by mental retardation, and those with organic brain disease. (bula de Divalproato de sódio (valproato), Advertência em caixa preta)

  • TopiramatoanticonvulsivanteGrave

    Children under the age of two years are at a considerably increased risk of developing fatal hepatotoxicity, especially those on multiple anticonvulsants, those with congenital metabolic disorders, those with severe seizure disorders accompanied by mental retardation, and those with organic brain disease. (bula de Divalproato de sódio (valproato), Advertência em caixa preta)

  • TramadolopioideGrave

    Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (bula de Tramadol, Advertência em caixa preta)

  • Risks from Concomitant Use with Benzodiazepines or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (bula de Tramadol + paracetamol, Advertência em caixa preta)

  • TriazolambenzodiazepínicoGrave

    • Effects on Driving and Operating Heavy Machinery : Patients receiving triazolam should be cautioned against driving or operating heavy machinery, as well as avoiding concomitant use with alcohol and other CNS depressant drugs. (bula de Triazolam, Advertências e precauções)

  • VigabatrinaanticonvulsivanteGrave

    Children under the age of two years are at a considerably increased risk of developing fatal hepatotoxicity, especially those on multiple anticonvulsants, those with congenital metabolic disorders, those with severe seizure disorders accompanied by mental retardation, and those with organic brain disease. (bula de Divalproato de sódio (valproato), Advertência em caixa preta)

  • Zaleplonasedativo-hipnóticoGrave

    The use of zaleplon with other sedative-hypnotics at bedtime or the middle of the night is not recommended (see ). (bula de Zaleplona, Advertências)

  • Zolpidemsedativo-hipnóticoGrave

    The use of Zolpidem Tartrate with other sedative-hypnotics (including other zolpidem products) at bedtime or the middle of the night is not recommended. (bula de Zolpidem, Advertências e precauções)

  • ZonisamidaanticonvulsivanteGrave

    Children under the age of two years are at a considerably increased risk of developing fatal hepatotoxicity, especially those on multiple anticonvulsants, those with congenital metabolic disorders, those with severe seizure disorders accompanied by mental retardation, and those with organic brain disease. (bula de Divalproato de sódio (valproato), Advertência em caixa preta)

Interações moderadas (163)

  • Acetazolamidainibidor da anidrase carbônicaModerada

    By decreasing the gastrointestinal absorption of primidone, acetazolamide may decrease serum concentrations of primidone and its metabolites, with a consequent possible decrease in anticonvulsant effect. (bula de Acetazolamida, Interações medicamentosas)

  • Aspirin, carbapenem antibiotics, estrogen-containing hormonal contraceptives, methotrexate: Monitoring of valproate concentrations is recommended ( 7.1 ) (bula de Divalproato de sódio (valproato), Interações medicamentosas)

  • Ácido acetilsalicílico + dipiridamolantiagregante plaquetárioModerada

    Aspirin, carbapenem antibiotics, estrogen-containing hormonal contraceptives, methotrexate: Monitoring of valproate concentrations is recommended ( 7.1 ) (bula de Divalproato de sódio (valproato), Interações medicamentosas)

  • Ácido fólico (folato)Vitaminas e mineraisModerada

    Evidence suggests that folic acid supplementation prior to conception and during the first trimester of pregnancy decreases the risk for congenital neural tube defects in the general population [see Use in Specific Populations ( 8.1 )] . (bula de Divalproato de sódio (valproato), Advertências e precauções)

  • AlbendazolModerada

    Risk of Neurologic Symptoms: Neurocysticercosis patients may experience cerebral hypertensive episodes, seizures or focal neurologic deficits after initiation of therapy; begin appropriate steroid and anticonvulsant therapy. (bula de Albendazol, Advertências e precauções)

  • Alopurinolinibidor da xantina oxidaseModerada

    Inform patients also that the central nervous system depressant effects of allopurinol tablets may be additive to those of alcohol and other CNS depressants. (bula de Alopurinol, Advertências e precauções)

  • AminofilinametilxantinaModerada

    25% increase Diazepam Benzodiazepines increase CNS concentrations of adenosine, a potent CNS depressant, while theophylline blocks adenosine receptors. (bula de Aminofilina, Interações medicamentosas)

  • Amitriptilinaantidepressivo tricíclicoModerada

    Dosage adjustment of amitriptyline/nortriptyline, propofol, warfarin, and zidovudine may be necessary if used concomitantly with Depakote ER ( 7.2 ) (bula de Divalproato de sódio (valproato), Interações medicamentosas)

  • Amoxapinaantidepressivo tricíclicoModerada

    Amoxapine may enhance the response to alcohol and the effects of barbiturates and other CNS depressants. (bula de Amoxapina, Interações medicamentosas)

  • ApixabanaanticoagulanteModerada

    The therapeutic relevance of this is unknown; however, coagulation tests should be monitored if valproate therapy is instituted in patients taking anticoagulants. (bula de Divalproato de sódio (valproato), Interações medicamentosas)

  • Aprepitantoinibidor da CYP3A4Moderada

    Hepatic enzyme-inducing drugs (e.g., phenytoin, carbamazepine, phenobarbital, primidone, rifampin) can increase valproate clearance, while enzyme inhibitors (e.g., felbamate) can decrease valproate clearance. (bula de Divalproato de sódio (valproato), Interações medicamentosas)

  • ArgatrobanaanticoagulanteModerada

    The therapeutic relevance of this is unknown; however, coagulation tests should be monitored if valproate therapy is instituted in patients taking anticoagulants. (bula de Divalproato de sódio (valproato), Interações medicamentosas)

  • Armodafinilaestimulante do SNCModerada

    Hepatic enzyme-inducing drugs (e.g., phenytoin, carbamazepine, phenobarbital, primidone, rifampin) can increase valproate clearance, while enzyme inhibitors (e.g., felbamate) can decrease valproate clearance. (bula de Divalproato de sódio (valproato), Interações medicamentosas)

  • Articaína + epinefrinaanestésico localModerada

    …cyclophosphamide, flutamide, hydroxyurea, ifosfamide, rasburicase Antibiotics dapsone, nitrofurantoin, para-aminosalicylic acid, sulfonamides Antimalarials chloroquine, primaquine Anticonvulsants phenobarbital, phenytoin, sodium valproate Other drugs acetaminophen, metoclopramide, quinine, sulfasalazine Monoamine Oxidase Inhibitors, Nonselective Beta-Adrenergic… (bula de Articaína + epinefrina, Interações medicamentosas)

  • Baclofenorelaxante muscularModerada

    Patients should also be cautioned that the central nervous system depressant effects of intrathecal baclofen may be additive to those of alcohol and other CNS depressants. (bula de Baclofeno, Advertências e precauções)

  • BeclometasonacorticosteroideModerada

    Patients with major risk factors for decreased bone mineral content, such as prolonged immobilization, family history of osteoporosis, or chronic use of drugs that can reduce bone mass (e.g., anticonvulsants and corticosteroids) should be monitored and treated with established standards of care. (bula de Beclometasona, Advertências e precauções)

  • Sedatives/Hypnotics: midazolam (oral) triazolam ↑ midazolam (oral) ↑ triazolam Use caution when midazolam or triazolam is concomitantly administered with BIXLENVO. (bula de Bictegravir + entricitabina + tenofovir alafenamida, Interações medicamentosas)

  • BivalirudinaanticoagulanteModerada

    The therapeutic relevance of this is unknown; however, coagulation tests should be monitored if valproate therapy is instituted in patients taking anticoagulants. (bula de Divalproato de sódio (valproato), Interações medicamentosas)

  • Bosentanaindutor da CYP3A4Moderada

    Hepatic enzyme-inducing drugs (e.g., phenytoin, carbamazepine, phenobarbital, primidone, rifampin) can increase valproate clearance, while enzyme inhibitors (e.g., felbamate) can decrease valproate clearance. (bula de Divalproato de sódio (valproato), Interações medicamentosas)

  • Brimonidinaagonista alfa-adrenérgicoModerada

    Use with CNS depressants may result in an additive or potentiating effect. (bula de Brimonidina, Interações medicamentosas)

  • Brimonidina + timololagonista alfa-adrenérgicoModerada

    Use with CNS depressants may result in an additive or potentiating effect. (bula de Brimonidina + timolol, Interações medicamentosas)

  • Central Nervous System (CNS) depressants Antihistamines have additive effects with alcohol and other CNS depressants (hypnotics, sedatives, tranquilizers, antianxiety agents, etc.). Antihypertensive drugs Sympathomimetic may reduce the effects of antihypertensive drugs. (bula de Bronfeniramina + pseudoefedrina + dextrometorfano, Interações medicamentosas)

  • BudesonidacorticosteroideModerada

    Patients with major risk factors for decreased bone mineral content, such as prolonged immobilization, family history of osteoporosis, post menopausal status, tobacco use, advance age, poor nutrition, or chronic use of drugs that can reduce bone mass (e.g., anticonvulsants, oral corticosteroids) should be monitored and treated with established standards of care. (bula de Budesonida, Advertências e precauções)

  • Budesonida + formoterolcorticosteroideModerada

    Patients with major risk factors for decreased bone mineral content, such as prolonged immobilization, family history of osteoporosis, postmenopausal status, tobacco use, advanced age, poor nutrition, or chronic use of drugs that can reduce bone mass (e.g., anticonvulsants, oral corticosteroids) should be monitored and treated with established standards of care. (bula de Budesonida + formoterol, Advertências e precauções)

  • Bupivacaínaanestésico localModerada

    Possible early warning signs of central nervous system (CNS) toxicity are restlessness, anxiety, incoherent speech, lightheadedness, numbness and tingling of the mouth and lips, metallic taste, tinnitus, dizziness, blurred vision, tremors, twitching, CNS depression, or drowsiness. (bula de Bupivacaína, Advertências e precauções)

  • Bupivacaína + epinefrinaanestésico localModerada

    Possible early warning signs of central nervous system (CNS) toxicity are restlessness, anxiety, incoherent speech, lightheadedness, numbness and tingling of the mouth and lips, metallic taste, tinnitus, dizziness, blurred vision, tremors, twitching, CNS depression, or drowsiness. (bula de Bupivacaína + epinefrina, Advertências e precauções)

  • Warn patients of the potential danger of self-administration of benzodiazepines or other CNS depressants while under treatment with buprenorphine and naloxone sublingual tablets [see Warnings and Precautions (5.3) , Drug Interactions (7) ] . (bula de Buprenorfina + naloxona, Advertências e precauções)

  • Buspironamedicamento serotoninérgicoModerada

    Triazolam/flurazepam: Coadministration of buspirone with either triazolam or flurazepam did not appear to prolong or intensify the sedative effects of either benzodiazepine. (bula de Buspirona, Interações medicamentosas)

  • Aspirin, carbapenem antibiotics, estrogen-containing hormonal contraceptives, methotrexate: Monitoring of valproate concentrations is recommended ( 7.1 ) (bula de Divalproato de sódio (valproato), Interações medicamentosas)

  • Butalbital + paracetamolbarbitúricoModerada

    All patients receiving concomitant barbiturate therapy should be closely monitored for neurological toxicity. (bula de Divalproato de sódio (valproato), Interações medicamentosas)

  • All patients receiving concomitant barbiturate therapy should be closely monitored for neurological toxicity. (bula de Divalproato de sódio (valproato), Interações medicamentosas)

  • Carisoprodolrelaxante muscularModerada

    • Additive sedative effects when used with other CNS depressants including alcohol (5.1) (bula de Carisoprodol, Advertências e precauções)

  • CBD (canabidiol)Tabaco e cannabisModerada

    Cannabidiol Concomitant administration of valproate and cannabidiol has been associated with an increased risk of ALT and/or AST elevation. (bula de Divalproato de sódio (valproato), Interações medicamentosas)

  • CiclesonidacorticosteroideModerada

    Patients with major risk factors for decreased bone mineral content, such as prolonged immobilization, family history of osteoporosis, or chronic use of drugs that can reduce bone mass (e.g., anticonvulsants and oral corticosteroids) should be monitored and treated with established standards of care. (bula de Ciclesonida, Advertências e precauções)

  • CiclosporinaimunossupressorModerada

    Drugs/Dietary Supplements That Decrease Cyclosporine Concentrations Antibiotics Anticonvulsants Other Drugs/Dietary Supplements nafcillin carbamazepine bosentan St. (bula de Ciclosporina, Interações medicamentosas)

  • Ciproeptadinaanti-histamínicoModerada

    CNS Depressants Antihistamines may have additive effects with alcohol and other CNS depressants, e.g., hypnotics, sedatives, tranquilizers, antianxiety agents. (bula de Ciproeptadina, Advertências)

  • Claritromicinaantibiótico macrolídeoModerada

    Antiepileptics: Carbamazepine Use With Caution Carbamazepine: Concomitant administration of single doses of clarithromycin and carbamazepine has been shown to result in increased plasma concentrations of carbamazepine. (bula de Claritromicina, Interações medicamentosas)

  • Clemastinaanti-histamínicoModerada

    Use with CNS Depressants Clemastine has additive effects with alcohol and other CNS depressants (hypnotics, sedatives, tranquilizers, etc.). Use in Activities Requiring Mental Alertness Patients should be warned about engaging in activities requiring mental alertness such as driving a car or operating appliances, machinery, etc. (bula de Clemastina, Advertências)

  • ClorazepatobenzodiazepínicoModerada

    The finding of increased risk with AEDs of varying mechanisms of action and across a range of indications suggests that the risk applies to all AEDs used for any indication. (bula de Clorazepato, Advertências)

  • ClordiazepóxidobenzodiazepínicoModerada

    The concomitant use of alcohol or other central nervous system depressants may have an additive effect. (bula de Clordiazepóxido, Advertências)

  • Clordiazepóxido + clidíniobenzodiazepínicoModerada

    Effects on the Ability to Drive or Operate Machinery As in the case of other preparations containing CNS-acting drugs, patients receiving Librax should be cautioned about possible combined effects with opioids, alcohol and other CNS depressants. (bula de Clordiazepóxido + clidínio, Advertências)

  • Cloroprocaínaanestésico localModerada

    …procaine, ropivacaine, tetracaine Antineoplastic agents cyclophosphamide, flutamide, hydroxyurea, ifosfamide, rasburicase Antibiotics dapsone, nitrofurantoin, para-aminosalicylic acid, sulfonamides Antimalarials chloroquine, primaquine Anticonvulsants Phenobarbital, phenytoin, sodium valproate Other drugs acetaminophen, metoclopramide, quinine, sulfasalazine (bula de Cloroprocaína, Precauções)

  • ClorpromazinaantipsicóticoModerada

    Therefore, dosage of anticonvulsants, including barbiturates, should not be reduced if chlorpromazine is started. (bula de Clorpromazina, Precauções)

  • Clorzoxazonarelaxante muscularModerada

    Chlorzoxazone use should also be discontinued if a patient develops abnormal liver enzymes (e.g., AST, ALT, alkaline phosphatase and bilirubin.) The concomitant use of alcohol or other central nervous system depressants may have an additive effect. (bula de Clorzoxazona, Advertências e precauções)

  • DabigatranaanticoagulanteModerada

    The therapeutic relevance of this is unknown; however, coagulation tests should be monitored if valproate therapy is instituted in patients taking anticoagulants. (bula de Divalproato de sódio (valproato), Interações medicamentosas)

  • Daridorexantosedativo-hipnóticoModerada

    Risk increases when used with other central nervous system (CNS) depressants. (bula de Daridorexanto, Advertências e precauções)

  • Deferasiroxsuplemento de ferroModerada

    Hepatic enzyme-inducing drugs (e.g., phenytoin, carbamazepine, phenobarbital, primidone, rifampin) can increase valproate clearance, while enzyme inhibitors (e.g., felbamate) can decrease valproate clearance. (bula de Divalproato de sódio (valproato), Interações medicamentosas)

  • Desogestrel + etinilestradiolanticoncepcional oralModerada

    Aspirin, carbapenem antibiotics, estrogen-containing hormonal contraceptives, methotrexate: Monitoring of valproate concentrations is recommended ( 7.1 ) (bula de Divalproato de sódio (valproato), Interações medicamentosas)

  • Deutetrabenazinainibidor do VMAT2Moderada

    Alcohol or other sedating drugs: May have additive sedation and somnolence ( 7.5 ) (bula de Deutetrabenazina, Interações medicamentosas)

  • DexametasonacorticosteroideModerada

    Hepatic enzyme-inducing drugs (e.g., phenytoin, carbamazepine, phenobarbital, primidone, rifampin) can increase valproate clearance, while enzyme inhibitors (e.g., felbamate) can decrease valproate clearance. (bula de Divalproato de sódio (valproato), Interações medicamentosas)

  • Dexclorfeniraminaanti-histamínicoModerada

    Use with CNS Depressants CORPHENA Oral Solution has additive effects with alcohol and other CNS depressants (hypnotics, sedatives, tranquilizers, etc.). Use in Activities Requiring Mental Alertness Patients should be warned about engaging in activities requiring mental alertness such as driving a car or operating appliances, machinery, etc. (bula de Dexclorfeniramina, Advertências)

  • Diacetato de etinodiol + etinilestradiolanticoncepcional oralModerada

    Aspirin, carbapenem antibiotics, estrogen-containing hormonal contraceptives, methotrexate: Monitoring of valproate concentrations is recommended ( 7.1 ) (bula de Divalproato de sódio (valproato), Interações medicamentosas)

  • DiazepambenzodiazepínicoModerada

    Co-administration of valproate (1,500 mg daily) increased the free fraction of diazepam (10 mg) by 90% in healthy volunteers (n=6). (bula de Divalproato de sódio (valproato), Interações medicamentosas)

  • DiclofenacoAINEModerada

    Exercise caution when prescribing ZIPSOR with concomitant drugs that are known to be potentially hepatotoxic (e.g., acetaminophen, antibiotics, antiepileptics). (bula de Diclofenaco, Advertências e precauções)

  • Exercise caution when prescribing diclofenac sodium/misoprostol with concomitant drugs that are known to be potentially hepatotoxic (e.g., antibiotics, anti-epileptics). (bula de Diclofenaco + misoprostol, Advertências e precauções)

  • Difenidraminaanti-histamínicoModerada

    Drug Interactions Diphenhydramine hydrochloride has additive effects with alcohol and other CNS depressants (hypnotics, sedatives, tranquilizers, etc). (bula de Difenidramina, Interações medicamentosas)

  • Dimenidrinatoanti-histamínicoModerada

    The concomitant use of alcohol or other central nervous system depressants may have an additive effect. (bula de Dimenidrinato, Advertências)

  • Doxepinaantidepressivo tricíclicoModerada

    Although behaviors such as "sleep-driving" may occur with hypnotics alone at therapeutic doses, the use of alcohol and other CNS depressants with hypnotics appears to increase the risk of such behaviors, as does the use of hypnotics at doses exceeding the maximum recommended dose. (bula de Doxepina, Advertências e precauções)

  • Doxiciclinaantibiótico da classe das tetraciclinasModerada

    Barbiturates and Anti-Epileptics Barbiturates, carbamazepine, and phenytoin decrease the half-life of doxycycline. (bula de Doxiciclina, Interações medicamentosas)

  • DronabinolcanabinoideModerada

    Seizures and Seizure-like Activity : Weigh the potential risk versus benefits before prescribing dronabinol oral solution to patients with a history of seizures, including those requiring anti-epileptic medication or with other factors that lower the seizure threshold. (bula de Dronabinol, Advertências e precauções)

  • Droperidolantagonista da dopaminaModerada

    Following the administration of droperidol, the dose of other CNS depressant drugs should be reduced. (bula de Droperidol, Interações medicamentosas)

  • Drospirenona + etinilestradiolanticoncepcional oralModerada

    Aspirin, carbapenem antibiotics, estrogen-containing hormonal contraceptives, methotrexate: Monitoring of valproate concentrations is recommended ( 7.1 ) (bula de Divalproato de sódio (valproato), Interações medicamentosas)

  • EdoxabanaanticoagulanteModerada

    The therapeutic relevance of this is unknown; however, coagulation tests should be monitored if valproate therapy is instituted in patients taking anticoagulants. (bula de Divalproato de sódio (valproato), Interações medicamentosas)

  • EfavirenzantirretroviralModerada

    Hepatic enzyme-inducing drugs (e.g., phenytoin, carbamazepine, phenobarbital, primidone, rifampin) can increase valproate clearance, while enzyme inhibitors (e.g., felbamate) can decrease valproate clearance. (bula de Divalproato de sódio (valproato), Interações medicamentosas)

  • Efavirenz + lamivudina + tenofovirantirretroviralModerada

    Hepatic enzyme-inducing drugs (e.g., phenytoin, carbamazepine, phenobarbital, primidone, rifampin) can increase valproate clearance, while enzyme inhibitors (e.g., felbamate) can decrease valproate clearance. (bula de Divalproato de sódio (valproato), Interações medicamentosas)

  • EnoxaparinaanticoagulanteModerada

    The therapeutic relevance of this is unknown; however, coagulation tests should be monitored if valproate therapy is instituted in patients taking anticoagulants. (bula de Divalproato de sódio (valproato), Interações medicamentosas)

  • Entricitabina + tenofovirantirretroviralModerada

    Other Agents Anticonvulsants: carbamazepine oxcarbazepine phenobarbital phenytoin ↓ TAF Consider alternative anticonvulsant. (bula de Entricitabina + tenofovir, Interações medicamentosas)

  • EscopolaminaanticolinérgicoModerada

    Weigh this potential risk against the benefits before prescribing TRANSDERM SCŌP to patients with a history of seizures, including those receiving anti-epileptic medication or who have risk factors that can lower the seizure threshold. (bula de Escopolamina, Advertências e precauções)

  • EstazolambenzodiazepínicoModerada

    Although behaviors such as sleep-driving may occur with sedative-hypnotics alone at therapeutic doses, the use of alcohol and other CNS depressants with sedative-hypnotics appears to increase the risk of such behaviors, as does the use of sedative-hypnotics at doses exceeding the maximum recommended dose. (bula de Estazolam, Advertências)

  • EstradiolestrogênioModerada

    Aspirin, carbapenem antibiotics, estrogen-containing hormonal contraceptives, methotrexate: Monitoring of valproate concentrations is recommended ( 7.1 ) (bula de Divalproato de sódio (valproato), Interações medicamentosas)

  • Estradiol + dienogesteanticoncepcional oralModerada

    Aspirin, carbapenem antibiotics, estrogen-containing hormonal contraceptives, methotrexate: Monitoring of valproate concentrations is recommended ( 7.1 ) (bula de Divalproato de sódio (valproato), Interações medicamentosas)

  • Estradiol + noretisteronaestrogênioModerada

    Aspirin, carbapenem antibiotics, estrogen-containing hormonal contraceptives, methotrexate: Monitoring of valproate concentrations is recommended ( 7.1 ) (bula de Divalproato de sódio (valproato), Interações medicamentosas)

  • Estrogênios conjugadosestrogênioModerada

    Aspirin, carbapenem antibiotics, estrogen-containing hormonal contraceptives, methotrexate: Monitoring of valproate concentrations is recommended ( 7.1 ) (bula de Divalproato de sódio (valproato), Interações medicamentosas)

  • Aspirin, carbapenem antibiotics, estrogen-containing hormonal contraceptives, methotrexate: Monitoring of valproate concentrations is recommended ( 7.1 ) (bula de Divalproato de sódio (valproato), Interações medicamentosas)

  • Aspirin, carbapenem antibiotics, estrogen-containing hormonal contraceptives, methotrexate: Monitoring of valproate concentrations is recommended ( 7.1 ) (bula de Divalproato de sódio (valproato), Interações medicamentosas)

  • Aspirin, carbapenem antibiotics, estrogen-containing hormonal contraceptives, methotrexate: Monitoring of valproate concentrations is recommended ( 7.1 ) (bula de Divalproato de sódio (valproato), Interações medicamentosas)

  • EtravirinaantirretroviralModerada

    Hepatic enzyme-inducing drugs (e.g., phenytoin, carbamazepine, phenobarbital, primidone, rifampin) can increase valproate clearance, while enzyme inhibitors (e.g., felbamate) can decrease valproate clearance. (bula de Divalproato de sódio (valproato), Interações medicamentosas)

  • Felodipinobloqueador dos canais de cálcio di-hidropiridínicoModerada

    Anticonvulsants - In a pharmacokinetic study, maximum plasma concentrations of felodipine were considerably lower in epileptic patients on long-term anticonvulsant therapy (e.g., phenytoin, carbamazepine, or phenobarbital) than in healthy volunteers. (bula de Felodipino, Interações medicamentosas)

  • Hepatic enzyme-inducing drugs (e.g., phenytoin, carbamazepine, phenobarbital, primidone, rifampin) can increase valproate clearance, while enzyme inhibitors (e.g., felbamate) can decrease valproate clearance. (bula de Divalproato de sódio (valproato), Interações medicamentosas)

  • Flibanserinadepressor do SNCModerada

    Exacerbated by other CNS depressants, and in settings where flibanserin concentrations are increased. (bula de Flibanserina, Advertências e precauções)

  • FlumazenilbenzodiazepínicoModerada

    Possible risk factors for seizures include: concurrent major sedative-hypnotic drug withdrawal, recent therapy with repeated doses of parenteral benzodiazepines, myoclonic jerking or seizure activity prior to flumazenil administration in overdose cases, or concurrent cyclic antidepressant poisoning. (bula de Flumazenil, Advertências)

  • FluoxetinaISRSModerada

    Anticonvulsants: Potential for elevated phenytoin and carbamazepine levels and clinical anticonvulsant toxicity ( 7.7 ) (bula de Fluoxetina, Interações medicamentosas)

  • FluticasonacorticosteroideModerada

    Patients with major risk factors for decreased bone mineral content, such as prolonged immobilization, family history of osteoporosis, postmenopausal status, tobacco use, advanced age, poor nutrition, or chronic use of drugs that can reduce bone mass (e.g., anticonvulsants, oral corticosteroids), should be monitored and treated with established standards of care. (bula de Fluticasona, Advertências e precauções)

  • Fluticasona + salmeterolcorticosteroideModerada

    Patients with major risk factors for decreased bone mineral content, such as prolonged immobilization, family history of osteoporosis, or chronic use of drugs that can reduce bone mass (e.g., anticonvulsants, oral corticosteroids) should be monitored and treated with established standards of care. (bula de Fluticasona + salmeterol, Advertências e precauções)

  • Effects of VYKOURA on Other Drugs Certain Antiepileptic Drugs Increase monitoring for seizure activity in patients taking certain concomitant antiepileptic drugs. (bula de Folinato de cálcio (leucovorina), Interações medicamentosas)

  • FondaparinuxanticoagulanteModerada

    The therapeutic relevance of this is unknown; however, coagulation tests should be monitored if valproate therapy is instituted in patients taking anticoagulants. (bula de Divalproato de sódio (valproato), Interações medicamentosas)

  • FulvestrantoestrogênioModerada

    Aspirin, carbapenem antibiotics, estrogen-containing hormonal contraceptives, methotrexate: Monitoring of valproate concentrations is recommended ( 7.1 ) (bula de Divalproato de sódio (valproato), Interações medicamentosas)

  • GlicopirrônioanticolinérgicoModerada

    Other Anticholinergic Drugs There is potential for an additive interaction between glycopyrrolate and concomitantly used anticholinergic drugs (e.g., tricyclic antidepressants, anti-epileptics, class I antiarrhythmics, anti­-spasmodics, amantadine) resulting in increased anticholinergic adverse reactions. (bula de Glicopirrônio, Interações medicamentosas)

  • GriseofulvinaantifúngicoModerada

    Hepatic enzyme-inducing drugs (e.g., phenytoin, carbamazepine, phenobarbital, primidone, rifampin) can increase valproate clearance, while enzyme inhibitors (e.g., felbamate) can decrease valproate clearance. (bula de Divalproato de sódio (valproato), Interações medicamentosas)

  • HeparinaanticoagulanteModerada

    The therapeutic relevance of this is unknown; however, coagulation tests should be monitored if valproate therapy is instituted in patients taking anticoagulants. (bula de Divalproato de sódio (valproato), Interações medicamentosas)

  • IrinotecanoModerada

    Strong CYP3A4 Inducers Exposure to irinotecan or its active metabolite SN-38 is substantially reduced in adult and pediatric patients concomitantly receiving the CYP3A4 enzyme-inducing anticonvulsants phenytoin, phenobarbital, carbamazepine, or St. (bula de Irinotecano, Interações medicamentosas)

  • Lamivudina + zidovudinaantirretroviralModerada

    Dosage adjustment of amitriptyline/nortriptyline, propofol, warfarin, and zidovudine may be necessary if used concomitantly with Depakote ER ( 7.2 ) (bula de Divalproato de sódio (valproato), Interações medicamentosas)

  • Ledipasvir + sofosbuvirantiviralModerada

    Anticonvulsants: carbamazepine phenytoin phenobarbital ↓ ledipasvir ↓ sofosbuvir Coadministration of ledipasvir and sofosbuvir with carbamazepine, phenytoin, or phenobarbital is expected to decrease the concentration of ledipasvir and sofosbuvir, leading to reduced therapeutic effect of ledipasvir and sofosbuvir. (bula de Ledipasvir + sofosbuvir, Interações medicamentosas)

  • Lemborexantosedativo-hipnóticoModerada

    Risk increases with dose and use with other central nervous system (CNS) depressants. (bula de Lemborexanto, Advertências e precauções)

  • LenacapavirantirretroviralModerada

    Anticonvulsants: carbamazepine oxcarbazepine phenobarbital phenytoin ↓ lenacapavir Concomitant administration of carbamazepine, oxcarbazepine, phenobarbital, or phenytoin may result in loss of therapeutic effect and development of resistance. (bula de Lenacapavir, Interações medicamentosas)

  • Effects of Leucovorin Products on Other Drugs Antiepileptic Drugs Folic acid in large amounts may counteract the antiepileptic effect of phenobarbital, phenytoin and primidone and increase the frequency of seizures in susceptible children. (bula de Levofolinato de cálcio (levoleucovorina), Interações medicamentosas)

  • LevonorgestrelprogestinaModerada

    Aspirin, carbapenem antibiotics, estrogen-containing hormonal contraceptives, methotrexate: Monitoring of valproate concentrations is recommended ( 7.1 ) (bula de Divalproato de sódio (valproato), Interações medicamentosas)

  • Levonorgestrel + etinilestradiolanticoncepcional oralModerada

    Aspirin, carbapenem antibiotics, estrogen-containing hormonal contraceptives, methotrexate: Monitoring of valproate concentrations is recommended ( 7.1 ) (bula de Divalproato de sódio (valproato), Interações medicamentosas)

  • Lidocaína + epinefrinaanestésico localModerada

    Possible early warning signs of central nervous system (CNS) toxicity are restlessness, anxiety, incoherent speech, lightheadedness, metallic taste, tinnitus, dizziness, blurred vision, tremors, twitching, CNS depression, or drowsiness. (bula de Lidocaína + epinefrina, Advertências e precauções)

  • Lidocaína + prilocaínaanestésico localModerada

    …prilocaine, procaine, ropivacaine, tetracaine Antineoplastic agents cyclophosphamide, flutamide, hydroxyurea, isofamide, rasburicase Antibiotics dapsone, nitrofurantoin, para-aminosalicylic acid, sufonamides Antimalarials chloroquine, primaquine Anticonvulsants Phenobarbital, phenytoin, sodium valproate Other drugs acetaminophen, metoclopramide, quinine, sulfasalazine (bula de Lidocaína + prilocaína, Interações medicamentosas)

  • Lofexidinaagonista alfa-adrenérgicoModerada

    Increased Risk of CNS Depression with Concomitant use of CNS Depressant Drugs : Lofexidine tablets potentiates the CNS depressant effects of benzodiazepines and may potentiate the CNS depressant effects of alcohol, barbiturates, and other sedating drugs. (bula de Lofexidina, Advertências e precauções)

  • Lorlatinibeindutor da CYP3A4Moderada

    Hepatic enzyme-inducing drugs (e.g., phenytoin, carbamazepine, phenobarbital, primidone, rifampin) can increase valproate clearance, while enzyme inhibitors (e.g., felbamate) can decrease valproate clearance. (bula de Divalproato de sódio (valproato), Interações medicamentosas)

  • Meclizinaanti-histamínicoModerada

    • Coadministration of meclizine hydrochloride with other CNS depressants, including alcohol, may result in increased CNS depression ( 7.1 ). (bula de Meclizina, Interações medicamentosas)

  • MedroxiprogesteronaprogestinaModerada

    Aspirin, carbapenem antibiotics, estrogen-containing hormonal contraceptives, methotrexate: Monitoring of valproate concentrations is recommended ( 7.1 ) (bula de Divalproato de sódio (valproato), Interações medicamentosas)

  • MefloquinaantimaláricoModerada

    Anticonvulsants In patients taking an anticonvulsant (e.g., valproic acid, carbamazepine, phenobarbital or phenytoin), the concomitant use of mefloquine may reduce seizure control by lowering the plasma levels of the anticonvulsant. (bula de Mefloquina, Interações medicamentosas)

  • MegestrolprogestinaModerada

    Aspirin, carbapenem antibiotics, estrogen-containing hormonal contraceptives, methotrexate: Monitoring of valproate concentrations is recommended ( 7.1 ) (bula de Divalproato de sódio (valproato), Interações medicamentosas)

  • Mepivacaínaanestésico localModerada

    …procaine, ropivacaine, tetracaine Antineoplastic agents cyclophosphamide, flutamide, hydroxyurea, ifosfamide, rasburicase Antibiotics dapsone, nitrofurantoin, para-aminosalicylic acid, sulfonamides Antimalarials chloroquine, primaquine Anticonvulsants phenobarbital, phenytoin, sodium valproate Other drugs acetaminophen, metoclopramide, quinine, sulfasalazine (bula de Mepivacaína, Interações medicamentosas)

  • Meprobamatodepressor do SNCModerada

    Additive Effects Since the effects of meprobamate and alcohol or meprobamate and other CNS depressants or psychotropic drugs may be additive,appropriate caution should be exercised with patients who take more than one of these agents simultaneously. (bula de Meprobamato, Advertências)

  • MetirosinaModerada

    Concurrent use of metyrosine with alcohol or other CNS depressants can increase their sedative effects. (bula de Metirosina, Interações medicamentosas)

  • Metocarbamolrelaxante muscularModerada

    Patients receiving ATMEKSI (methocarbamol) Oral Suspension should be cautioned about combined effects with alcohol and other CNS depressants [ see Drug Interactions (7.1) ]. (bula de Metocarbamol, Advertências e precauções)

  • MetoexitalbarbitúricoModerada

    All patients receiving concomitant barbiturate therapy should be closely monitored for neurological toxicity. (bula de Divalproato de sódio (valproato), Interações medicamentosas)

  • MetotrexatoimunossupressorModerada

    Aspirin, carbapenem antibiotics, estrogen-containing hormonal contraceptives, methotrexate: Monitoring of valproate concentrations is recommended ( 7.1 ) (bula de Divalproato de sódio (valproato), Interações medicamentosas)

  • Mifepristonainibidor da CYP3A4Moderada

    Aspirin, carbapenem antibiotics, estrogen-containing hormonal contraceptives, methotrexate: Monitoring of valproate concentrations is recommended ( 7.1 ) (bula de Divalproato de sódio (valproato), Interações medicamentosas)

  • Mitapivateindutor da CYP3A4Moderada

    Hepatic enzyme-inducing drugs (e.g., phenytoin, carbamazepine, phenobarbital, primidone, rifampin) can increase valproate clearance, while enzyme inhibitors (e.g., felbamate) can decrease valproate clearance. (bula de Divalproato de sódio (valproato), Interações medicamentosas)

  • Mitotanoindutor da CYP3A4Moderada

    Hepatic enzyme-inducing drugs (e.g., phenytoin, carbamazepine, phenobarbital, primidone, rifampin) can increase valproate clearance, while enzyme inhibitors (e.g., felbamate) can decrease valproate clearance. (bula de Divalproato de sódio (valproato), Interações medicamentosas)

  • Modafinilaestimulante do SNCModerada

    Hepatic enzyme-inducing drugs (e.g., phenytoin, carbamazepine, phenobarbital, primidone, rifampin) can increase valproate clearance, while enzyme inhibitors (e.g., felbamate) can decrease valproate clearance. (bula de Divalproato de sódio (valproato), Interações medicamentosas)

  • MometasonacorticosteroideModerada

    Patients with major risk factors for decreased bone mineral content, such as prolonged immobilization, family history of osteoporosis, or chronic use of drugs that can reduce bone mass (e.g., anticonvulsants and corticosteroids) should be monitored and treated with established standards of care. (bula de Mometasona, Advertências e precauções)

  • Nafcilinaantibiótico da classe das penicilinasModerada

    Hepatic enzyme-inducing drugs (e.g., phenytoin, carbamazepine, phenobarbital, primidone, rifampin) can increase valproate clearance, while enzyme inhibitors (e.g., felbamate) can decrease valproate clearance. (bula de Divalproato de sódio (valproato), Interações medicamentosas)

  • Naloxonaantagonista opioideModerada

    WARNINGS AND PRECAUTIONS Risk of Recurrent Respiratory and CNS Depression : Due to the duration of action of naloxone relative to the opioid, respiratory and CNS depression may recur after the first dose of naloxone. (bula de Naloxona, Advertências e precauções)

  • NevirapinaantirretroviralModerada

    Hepatic enzyme-inducing drugs (e.g., phenytoin, carbamazepine, phenobarbital, primidone, rifampin) can increase valproate clearance, while enzyme inhibitors (e.g., felbamate) can decrease valproate clearance. (bula de Divalproato de sódio (valproato), Interações medicamentosas)

  • Aspirin, carbapenem antibiotics, estrogen-containing hormonal contraceptives, methotrexate: Monitoring of valproate concentrations is recommended ( 7.1 ) (bula de Divalproato de sódio (valproato), Interações medicamentosas)

  • NoretisteronaprogestinaModerada

    Aspirin, carbapenem antibiotics, estrogen-containing hormonal contraceptives, methotrexate: Monitoring of valproate concentrations is recommended ( 7.1 ) (bula de Divalproato de sódio (valproato), Interações medicamentosas)

  • Noretisterona + etinilestradiolanticoncepcional oralModerada

    Aspirin, carbapenem antibiotics, estrogen-containing hormonal contraceptives, methotrexate: Monitoring of valproate concentrations is recommended ( 7.1 ) (bula de Divalproato de sódio (valproato), Interações medicamentosas)

  • Norgestimato + etinilestradiolanticoncepcional oralModerada

    Aspirin, carbapenem antibiotics, estrogen-containing hormonal contraceptives, methotrexate: Monitoring of valproate concentrations is recommended ( 7.1 ) (bula de Divalproato de sódio (valproato), Interações medicamentosas)

  • Norgestrel + etinilestradiolanticoncepcional oralModerada

    Aspirin, carbapenem antibiotics, estrogen-containing hormonal contraceptives, methotrexate: Monitoring of valproate concentrations is recommended ( 7.1 ) (bula de Divalproato de sódio (valproato), Interações medicamentosas)

  • Nortriptilinaantidepressivo tricíclicoModerada

    Dosage adjustment of amitriptyline/nortriptyline, propofol, warfarin, and zidovudine may be necessary if used concomitantly with Depakote ER ( 7.2 ) (bula de Divalproato de sódio (valproato), Interações medicamentosas)

  • Olanzapina + fluoxetinaantipsicóticoModerada

    Carbamazepine : Potential for elevated carbamazepine levels and clinical anticonvulsant toxicity ( 7.7 ) (bula de Olanzapina + fluoxetina, Interações medicamentosas)

  • Aspirin, carbapenem antibiotics, estrogen-containing hormonal contraceptives, methotrexate: Monitoring of valproate concentrations is recommended ( 7.1 ) (bula de Divalproato de sódio (valproato), Interações medicamentosas)

  • OrlistateModerada

    Drug Interactions and Decreased Vitamin Absorption ORLISTAT may interact with concomitant drugs including cyclosporine, levothyroxine, warfarin, amiodarone, antiepileptic drugs, and antiretroviral drugs [see Drug Interactions (7) ]. (bula de Orlistate, Advertências e precauções)

  • OxazepambenzodiazepínicoModerada

    Patients should be warned that the effects of alcohol or other CNS-depressant drugs may be additive to those of Oxazepam, possibly requiring adjustment of dosage or elimination of such agents. (bula de Oxazepam, Advertências)

  • PerfenazinaantipsicóticoModerada

    If the patient is being treated with an anticonvulsant agent, increased dosage of that agent may be required when perphenazine products are used concomitantly. (bula de Perfenazina, Advertências)

  • Posaconazolantifúngico azólicoModerada

    Concomitant Use with Midazolam : Noxafil can prolong hypnotic/sedative effects. (bula de Posaconazol, Advertências e precauções)

  • Prilocaína + epinefrinaanestésico localModerada

    …cyclophosphamide, flutamide, hydroxyurea, ifosfamide, rasburicase Antibiotics dapsone, nitrofurantoin, para-aminosalicylic acid, sulfonamides Antimalarials chloroquine, primaquine Anticonvulsants phenobarbital, phenytoin, sodium valproate Other drugs acetaminophen, metoclopramide, quinine, sulfasalazine The administration of local anesthetic injections containing… (bula de Prilocaína + epinefrina, Interações medicamentosas)

  • ProclorperazinaantipsicóticoModerada

    Phenothiazines may lower the convulsive threshold; dosage adjustments of anticonvulsants may be necessary. (bula de Proclorperazina, Precauções)

  • ProgesteronaprogestinaModerada

    Aspirin, carbapenem antibiotics, estrogen-containing hormonal contraceptives, methotrexate: Monitoring of valproate concentrations is recommended ( 7.1 ) (bula de Divalproato de sódio (valproato), Interações medicamentosas)

  • Prometazinaanti-histamínicoModerada

    The impairment may be amplified by concomitant use of other central-nervous-system depressants such as alcohol, sedatives/hypnotics (including barbiturates), narcotics, narcotic analgesics, general anesthetics, tricyclic antidepressants, and tranquilizers; therefore such agents should either be eliminated or given in reduced dosage in the presence of promethazine… (bula de Prometazina, Advertências)

  • Prometazina + dextrometorfanoanti-histamínicoModerada

    The impairment may be amplified by concomitant use of other central-nervous-system depressants such as alcohol, sedatives/hypnotics (including barbiturates), narcotics, narcotic analgesics, general anesthetics, tricyclic antidepressants, and tranquilizers; therefore such agents should either be eliminated or given in reduced dosage in the presence of promethazine… (bula de Prometazina + dextrometorfano, Advertências)

  • Propofoldepressor do SNCModerada

    Dosage adjustment of amitriptyline/nortriptyline, propofol, warfarin, and zidovudine may be necessary if used concomitantly with Depakote ER ( 7.2 ) (bula de Divalproato de sódio (valproato), Interações medicamentosas)

  • Protriptilinaantidepressivo tricíclicoModerada

    Protriptyline may enhance the response to alcohol and the effects of barbiturates and other CNS depressants. (bula de Protriptilina, Interações medicamentosas)

  • Ramelteonasedativo-hipnóticoModerada

    The use of alcohol and other CNS depressants may increase the risk of such behaviors. (bula de Ramelteona, Advertências e precauções)

  • RifabutinaantibióticoModerada

    Hepatic enzyme-inducing drugs (e.g., phenytoin, carbamazepine, phenobarbital, primidone, rifampin) can increase valproate clearance, while enzyme inhibitors (e.g., felbamate) can decrease valproate clearance. (bula de Divalproato de sódio (valproato), Interações medicamentosas)

  • RifampicinaantibióticoModerada

    Rifampin A study involving the administration of a single dose of valproate (7 mg/kg) 36 hours after 5 nights of daily dosing with rifampin (600 mg) revealed a 40% increase in the oral clearance of valproate. (bula de Divalproato de sódio (valproato), Interações medicamentosas)

  • RifapentinaantibióticoModerada

    Hepatic enzyme-inducing drugs (e.g., phenytoin, carbamazepine, phenobarbital, primidone, rifampin) can increase valproate clearance, while enzyme inhibitors (e.g., felbamate) can decrease valproate clearance. (bula de Divalproato de sódio (valproato), Interações medicamentosas)

  • RivaroxabanaanticoagulanteModerada

    The therapeutic relevance of this is unknown; however, coagulation tests should be monitored if valproate therapy is instituted in patients taking anticoagulants. (bula de Divalproato de sódio (valproato), Interações medicamentosas)

  • Rocurôniobloqueador neuromuscularModerada

    Reduced Rocuronium Bromide Injection activity possible : Anticonvulsants. (bula de Rocurônio, Interações medicamentosas)

  • Ropivacaínaanestésico localModerada

    …cyclophosphamide, flutamide, hydroxyurea, ifosfamide, rasburicase Antibiotics dapsone, nitrofurantoin, para-aminosalicylic acid, sulfonamides Antimalarials chloroquine, primaquine Anticonvulsants Phenobarbital, phenytoin, sodium valproate Other drugs acetaminophen, metoclopramide, quinine, sulfasalazine NAROPIN should be used with caution in patients receiving… (bula de Ropivacaína, Interações medicamentosas)

  • Suvorexantosedativo-hipnóticoModerada

    Co-administration with other CNS depressants (e.g., benzodiazepines, opioids, tricyclic antidepressants, alcohol) increases the risk of CNS depression. (bula de Suvorexanto, Advertências e precauções)

  • Suzetriginaindutor da CYP3A4Moderada

    Hepatic enzyme-inducing drugs (e.g., phenytoin, carbamazepine, phenobarbital, primidone, rifampin) can increase valproate clearance, while enzyme inhibitors (e.g., felbamate) can decrease valproate clearance. (bula de Divalproato de sódio (valproato), Interações medicamentosas)

  • TacrolimoimunossupressorModerada

    Strong CYP3A Inducers c : Antimycobacterials (e.g., rifampin, rifabutin), anticonvulsants (e.g., phenytoin, carbamazepine and phenobarbital), St John’s wort May decrease tacrolimus whole blood trough concentrations and increase the risk of rejection [see Warnings and Precautions ( 5.10 )]. (bula de Tacrolimo, Interações medicamentosas)

  • TemazepambenzodiazepínicoModerada

    Although behaviors such as “sleep-driving” may occur with temazepam capsules alone at therapeutic doses, the use of alcohol and other CNS depressants with temazepam capsules appear to increase the risk of such behaviors, as does the use of temazepam capsules at doses exceeding the maximum recommended dose. (bula de Temazepam, Advertências)

  • TeofilinametilxantinaModerada

    25% increase Diazepam Benzodiazepines increase CNS concentrations of adenosine, a potent CNS depressant, while theophylline blocks adenosine receptors. (bula de Teofilina, Interações medicamentosas)

  • Tetrabenazinainibidor do VMAT2Moderada

    Alcohol or Other Sedating Drugs Concomitant use of alcohol or other sedating drugs may have additive effects and worsen sedation and somnolence [see Warnings and Precautions (5.7) ] . (bula de Tetrabenazina, Interações medicamentosas)

  • TinidazolantibióticoModerada

    Phenytoin, fosphenytoin: Adjustment of anticonvulsant and/or tinidazole dose(s) may be needed ( 7.1, 7.2 ) (bula de Tinidazol, Interações medicamentosas)

  • Tizanidinarelaxante muscularModerada

    Sedation: Zanaflex may interfere with everyday activities; sedative effects of Zanaflex, alcohol, and other central nervous system (CNS) depressants are additive ( 5.3 , 7.4 ) (bula de Tizanidina, Advertências e precauções)

  • Tranilciprominainibidor da MAOModerada

    Excessive reduction of blood glucose (additive effect) f CNS depressant agents (including opioids, alcohol, sedatives, hypnotics) Use with caution d Increased CNS depression Dietary supplements containing sympathomimetics Contraindicated a Antidepressants including but not limited to: Other MAOIs (e.g., linezolid, intravenous methylene blue, selective MAOIs)… (bula de Tranilcipromina, Interações medicamentosas)

  • TrazodonaantidepressivoModerada

    Intervention: Patients should be counseled that RALDESY may enhance the response to alcohol, barbiturates, and other CNS depressants. (bula de Trazodona, Interações medicamentosas)

  • TriexifenidilanticolinérgicoModerada

    Concurrent use of alcohol or other CNS depressants with trihexyphenidyl may cause increased sedative effects. (bula de Triexifenidil, Interações medicamentosas)

  • TrifluoperazinaantipsicóticoModerada

    Phenothiazines may lower the convulsive threshold; dosage adjustments of anticonvulsants may be necessary. (bula de Trifluoperazina, Precauções)

  • The recent use of other drugs that cause CNS depression or EPS symptoms may also increase the risk; consider reducing the dosage or discontinuing the drug. (bula de Trimetobenzamida, Advertências e precauções)

  • VarfarinaanticoagulanteModerada

    Dosage adjustment of amitriptyline/nortriptyline, propofol, warfarin, and zidovudine may be necessary if used concomitantly with Depakote ER ( 7.2 ) (bula de Divalproato de sódio (valproato), Interações medicamentosas)

  • VincristinaModerada

    Drug Interactions The simultaneous oral or intravenous administration of phenytoin and antineoplastic chemotherapy combinations that included vincristine sulfate has been reported to reduce blood levels of the anticonvulsant and to increase seizure activity. (bula de Vincristina, Interações medicamentosas)

  • Voriconazolantifúngico azólicoModerada

    Eszopiclone (CYP3A4 Inhibition) Not Studied In Vivo or In Vitro , but Drug Plasma Exposure Likely to be Increased which may Increase the Sedative Effect of Eszopiclone Dose reduction of eszopiclone is recommended. (bula de Voriconazol, Interações medicamentosas)

  • ZidovudinaantirretroviralModerada

    Dosage adjustment of amitriptyline/nortriptyline, propofol, warfarin, and zidovudine may be necessary if used concomitantly with Depakote ER ( 7.2 ) (bula de Divalproato de sódio (valproato), Interações medicamentosas)

Menções leves (44)

  • AbacavirantirretroviralLeve

    Additionally, the relevance of these in vitro findings is uncertain for patients receiving maximally suppressive antiretroviral therapy. (bula de Divalproato de sódio (valproato), Advertências e precauções)

  • Abacavir + lamivudinaantirretroviralLeve

    Additionally, the relevance of these in vitro findings is uncertain for patients receiving maximally suppressive antiretroviral therapy. (bula de Divalproato de sódio (valproato), Advertências e precauções)

  • The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (bula de Alfaepoetina, Advertências e precauções)

  • CefalexinacefalosporinaLeve

    Anticonvulsant therapy can be given if clinically indicated. (bula de Cefalexina, Advertências e precauções)

  • CefazolinacefalosporinaLeve

    Anticonvulsant therapy should be continued in patients with known seizure disorders. (bula de Cefazolina, Advertências e precauções)

  • CetorolacoAINELeve

    Antiepileptic Drugs Sporadic cases of seizures have been reported during concomitant use of ketorolac tromethamine and antiepileptic drugs (phenytoin, carbamazepine). (bula de Cetorolaco, Interações medicamentosas)

  • CitalopramISRSLeve

    In contrast, drugs that are inhibitors of cytochrome P450 isozymes, e.g., antidepressants, may be expected to have little effect on valproate clearance because cytochrome P450 microsomal mediated oxidation is a relatively minor secondary metabolic pathway compared to glucuronidation and beta-oxidation. (bula de Divalproato de sódio (valproato), Interações medicamentosas)

  • Clomipraminaantidepressivo tricíclicoLeve

    In contrast, drugs that are inhibitors of cytochrome P450 isozymes, e.g., antidepressants, may be expected to have little effect on valproate clearance because cytochrome P450 microsomal mediated oxidation is a relatively minor secondary metabolic pathway compared to glucuronidation and beta-oxidation. (bula de Divalproato de sódio (valproato), Interações medicamentosas)

  • Desipraminaantidepressivo tricíclicoLeve

    In contrast, drugs that are inhibitors of cytochrome P450 isozymes, e.g., antidepressants, may be expected to have little effect on valproate clearance because cytochrome P450 microsomal mediated oxidation is a relatively minor secondary metabolic pathway compared to glucuronidation and beta-oxidation. (bula de Divalproato de sódio (valproato), Interações medicamentosas)

  • In contrast, drugs that are inhibitors of cytochrome P450 isozymes, e.g., antidepressants, may be expected to have little effect on valproate clearance because cytochrome P450 microsomal mediated oxidation is a relatively minor secondary metabolic pathway compared to glucuronidation and beta-oxidation. (bula de Divalproato de sódio (valproato), Interações medicamentosas)

  • Dextroanfetaminaestimulante do SNCLeve

    Antihistamines Amphetamines may counteract the sedative effect of antihistamines. (bula de Dextroanfetamina, Interações medicamentosas)

  • DolutegravirantirretroviralLeve

    Additionally, the relevance of these in vitro findings is uncertain for patients receiving maximally suppressive antiretroviral therapy. (bula de Divalproato de sódio (valproato), Advertências e precauções)

  • In Drug-Induced CNS and Respiratory Depression Doxapram alone may not stimulate adequate spontaneous breathing or provide sufficient arousal in patients who are severely depressed either due to respiratory failure or to CNS depressant drugs, but may be used as an adjunct to established supportive measures and resuscitative techniques. (bula de Doxapram, Advertências)

  • Doxilamina + piridoxinaanti-histamínicoLeve

    Concurrent use of alcohol and other CNS depressants (such as hypnotic sedatives and tranquilizers) with doxylamine succinate and pyridoxine hydrochloride delayed-release tablets is not recommended. (bula de Doxilamina + piridoxina, Interações medicamentosas)

  • DuloxetinaIRSNLeve

    In contrast, drugs that are inhibitors of cytochrome P450 isozymes, e.g., antidepressants, may be expected to have little effect on valproate clearance because cytochrome P450 microsomal mediated oxidation is a relatively minor secondary metabolic pathway compared to glucuronidation and beta-oxidation. (bula de Divalproato de sódio (valproato), Interações medicamentosas)

  • EntricitabinaantirretroviralLeve

    Additionally, the relevance of these in vitro findings is uncertain for patients receiving maximally suppressive antiretroviral therapy. (bula de Divalproato de sódio (valproato), Advertências e precauções)

  • EscitalopramISRSLeve

    In contrast, drugs that are inhibitors of cytochrome P450 isozymes, e.g., antidepressants, may be expected to have little effect on valproate clearance because cytochrome P450 microsomal mediated oxidation is a relatively minor secondary metabolic pathway compared to glucuronidation and beta-oxidation. (bula de Divalproato de sódio (valproato), Interações medicamentosas)

  • FluvoxaminaISRSLeve

    In contrast, drugs that are inhibitors of cytochrome P450 isozymes, e.g., antidepressants, may be expected to have little effect on valproate clearance because cytochrome P450 microsomal mediated oxidation is a relatively minor secondary metabolic pathway compared to glucuronidation and beta-oxidation. (bula de Divalproato de sódio (valproato), Interações medicamentosas)

  • HidrocortisonacorticosteroideLeve

    Examples: Anticonvulsants: phenytoin, carbamazepine and oxcarbazepine Antibiotics: rifampicin and rifabutin Barbiturates: phenobarbital and primidone Antiretrovirals: efavirenz and nevirapine Estrogen and Estrogen Containing Products Clinical Impact: Oral estrogen and estrogen-containing oral contraceptives may interact with hydrocortisone by increasing serum… (bula de Hidrocortisona, Interações medicamentosas)

  • Hidroxicloroquinamedicamento que prolonga o intervalo QTLeve

    Antiepileptics The activity of antiepileptic drugs might be impaired if co-administered with PLAQUENIL. (bula de Hidroxicloroquina, Interações medicamentosas)

  • Imipraminaantidepressivo tricíclicoLeve

    In contrast, drugs that are inhibitors of cytochrome P450 isozymes, e.g., antidepressants, may be expected to have little effect on valproate clearance because cytochrome P450 microsomal mediated oxidation is a relatively minor secondary metabolic pathway compared to glucuronidation and beta-oxidation. (bula de Divalproato de sódio (valproato), Interações medicamentosas)

  • LamivudinaantirretroviralLeve

    Additionally, the relevance of these in vitro findings is uncertain for patients receiving maximally suppressive antiretroviral therapy. (bula de Divalproato de sódio (valproato), Advertências e precauções)

  • In contrast, drugs that are inhibitors of cytochrome P450 isozymes, e.g., antidepressants, may be expected to have little effect on valproate clearance because cytochrome P450 microsomal mediated oxidation is a relatively minor secondary metabolic pathway compared to glucuronidation and beta-oxidation. (bula de Divalproato de sódio (valproato), Interações medicamentosas)

  • Levotiroxinahormônio tireoidianoLeve

    Effect on Ketone and Thyroid Function Tests Valproate is partially eliminated in the urine as a keto-metabolite which may lead to a false interpretation of the urine ketone test. (bula de Divalproato de sódio (valproato), Advertências e precauções)

  • Levotiroxina + liotironinahormônio tireoidianoLeve

    Effect on Ketone and Thyroid Function Tests Valproate is partially eliminated in the urine as a keto-metabolite which may lead to a false interpretation of the urine ketone test. (bula de Divalproato de sódio (valproato), Advertências e precauções)

  • Liotironinahormônio tireoidianoLeve

    Effect on Ketone and Thyroid Function Tests Valproate is partially eliminated in the urine as a keto-metabolite which may lead to a false interpretation of the urine ketone test. (bula de Divalproato de sódio (valproato), Advertências e precauções)

  • LoxapinaantipsicóticoLeve

    Therefore, ambulatory patients should be warned about activities requiring alertness (e.g., operating vehicles or machinery) and about concomitant use of alcohol and other CNS depressants. (bula de Loxapina, Advertências)

  • MaraviroqueantirretroviralLeve

    Additionally, the relevance of these in vitro findings is uncertain for patients receiving maximally suppressive antiretroviral therapy. (bula de Divalproato de sódio (valproato), Advertências e precauções)

  • Anticonvulsants, psychotropic, hormone preparations, corticosteroids, antithyroid agents, cyproheptadine: may affect the results of the metyrapone test. (bula de Metirapona, Interações medicamentosas)

  • MirtazapinaantidepressivoLeve

    In contrast, drugs that are inhibitors of cytochrome P450 isozymes, e.g., antidepressants, may be expected to have little effect on valproate clearance because cytochrome P450 microsomal mediated oxidation is a relatively minor secondary metabolic pathway compared to glucuronidation and beta-oxidation. (bula de Divalproato de sódio (valproato), Interações medicamentosas)

  • NefazodonaantidepressivoLeve

    In contrast, drugs that are inhibitors of cytochrome P450 isozymes, e.g., antidepressants, may be expected to have little effect on valproate clearance because cytochrome P450 microsomal mediated oxidation is a relatively minor secondary metabolic pathway compared to glucuronidation and beta-oxidation. (bula de Divalproato de sódio (valproato), Interações medicamentosas)

  • ParoxetinaISRSLeve

    In contrast, drugs that are inhibitors of cytochrome P450 isozymes, e.g., antidepressants, may be expected to have little effect on valproate clearance because cytochrome P450 microsomal mediated oxidation is a relatively minor secondary metabolic pathway compared to glucuronidation and beta-oxidation. (bula de Divalproato de sódio (valproato), Interações medicamentosas)

  • PrazosinaalfabloqueadorLeve

    …to date with the following: (1) cardiac glycosides– digitalis and digoxin; (2) hypoglycemics–insulin, chlorpropamide, phenformin, tolazamide, and tolbutamide; (3) tranquilizers and sedatives–chlordiazepoxide, diazepam, and phenobarbital; (4) antigout–allopurinol, colchicine, and probenecid; (5) antiarrhythmics–procainamide, propranolol (see WARNINGS however),… (bula de Prazosina, Interações medicamentosas)

  • Propiltiouracilamedicamento antitireoidianoLeve

    Effect on Ketone and Thyroid Function Tests Valproate is partially eliminated in the urine as a keto-metabolite which may lead to a false interpretation of the urine ketone test. (bula de Divalproato de sódio (valproato), Advertências e precauções)

  • RaltegravirantirretroviralLeve

    Additionally, the relevance of these in vitro findings is uncertain for patients receiving maximally suppressive antiretroviral therapy. (bula de Divalproato de sódio (valproato), Advertências e precauções)

  • SertralinaISRSLeve

    In contrast, drugs that are inhibitors of cytochrome P450 isozymes, e.g., antidepressants, may be expected to have little effect on valproate clearance because cytochrome P450 microsomal mediated oxidation is a relatively minor secondary metabolic pathway compared to glucuronidation and beta-oxidation. (bula de Divalproato de sódio (valproato), Interações medicamentosas)

  • TenofovirantirretroviralLeve

    Additionally, the relevance of these in vitro findings is uncertain for patients receiving maximally suppressive antiretroviral therapy. (bula de Divalproato de sódio (valproato), Advertências e precauções)

  • Teriparatidahormônio tireoidianoLeve

    Effect on Ketone and Thyroid Function Tests Valproate is partially eliminated in the urine as a keto-metabolite which may lead to a false interpretation of the urine ketone test. (bula de Divalproato de sódio (valproato), Advertências e precauções)

  • These data suggest that GH may alter the clearance of compounds known to be metabolized by CYP450 liver enzymes (e.g., corticosteroids, sex steroids, anticonvulsants, and cyclosporine). (bula de Tesamorrelina, Interações medicamentosas)

  • Tiamazol (metimazol)medicamento antitireoidianoLeve

    Effect on Ketone and Thyroid Function Tests Valproate is partially eliminated in the urine as a keto-metabolite which may lead to a false interpretation of the urine ketone test. (bula de Divalproato de sódio (valproato), Advertências e precauções)

  • Trimipraminaantidepressivo tricíclicoLeve

    In contrast, drugs that are inhibitors of cytochrome P450 isozymes, e.g., antidepressants, may be expected to have little effect on valproate clearance because cytochrome P450 microsomal mediated oxidation is a relatively minor secondary metabolic pathway compared to glucuronidation and beta-oxidation. (bula de Divalproato de sódio (valproato), Interações medicamentosas)

  • VenlafaxinaIRSNLeve

    In contrast, drugs that are inhibitors of cytochrome P450 isozymes, e.g., antidepressants, may be expected to have little effect on valproate clearance because cytochrome P450 microsomal mediated oxidation is a relatively minor secondary metabolic pathway compared to glucuronidation and beta-oxidation. (bula de Divalproato de sódio (valproato), Interações medicamentosas)

  • VilazodonaISRSLeve

    In contrast, drugs that are inhibitors of cytochrome P450 isozymes, e.g., antidepressants, may be expected to have little effect on valproate clearance because cytochrome P450 microsomal mediated oxidation is a relatively minor secondary metabolic pathway compared to glucuronidation and beta-oxidation. (bula de Divalproato de sódio (valproato), Interações medicamentosas)

  • VortioxetinaantidepressivoLeve

    In contrast, drugs that are inhibitors of cytochrome P450 isozymes, e.g., antidepressants, may be expected to have little effect on valproate clearance because cytochrome P450 microsomal mediated oxidation is a relatively minor secondary metabolic pathway compared to glucuronidation and beta-oxidation. (bula de Divalproato de sódio (valproato), Interações medicamentosas)

Nenhuma interação significativa relatada (1)

  • Montelucasteantagonista do receptor de leucotrienosSem interação

    …adjustment is needed when SINGULAIR is co-administered with theophylline, prednisone, prednisolone, oral contraceptives, fexofenadine, digoxin, warfarin, gemfibrozil, itraconazole, thyroid hormones, sedative hypnotics, non-steroidal anti-inflammatory agents, benzodiazepines, decongestants, and Cytochrome P450 (CYP) enzyme inducers [see Clinical Pharmacology (12.3) ]. (bula de Montelucaste, Interações medicamentosas)

Verifique Divalproato de sódio (valproato) com tudo o que você toma. Adicione sua lista completa; todos os pares são verificados de uma vez.

Abrir no verificador

Não é aconselhamento médico. A gravidade reflete a redação da bula, não as suas circunstâncias. Um alerta “grave” pode ser rotina sob supervisão, e um “leve” pode ser importante em doses altas. Pergunte a um farmacêutico.